 David Douglass
Concepts (94)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 2 | 2025 | 72 | 1.010 |
Why?
| | Fibromatosis, Aggressive | 1 | 2022 | 3 | 0.760 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2022 | 5 | 0.760 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2021 | 8 | 0.710 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2021 | 11 | 0.710 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2020 | 5 | 0.650 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2020 | 8 | 0.650 |
Why?
| | Sarcoma, Ewing | 1 | 2020 | 32 | 0.640 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2021 | 228 | 0.620 |
Why?
| | Mutation | 2 | 2022 | 1337 | 0.590 |
Why?
| | Antineoplastic Agents | 2 | 2025 | 1232 | 0.540 |
Why?
| | DNA-Binding Proteins | 1 | 2020 | 423 | 0.540 |
Why?
| | Transcription Factors | 1 | 2020 | 571 | 0.510 |
Why?
| | Soft Tissue Neoplasms | 2 | 2025 | 62 | 0.420 |
Why?
| | Breast Neoplasms | 1 | 2021 | 1222 | 0.380 |
Why?
| | Prognosis | 3 | 2024 | 2118 | 0.300 |
Why?
| | Adolescent | 4 | 2025 | 6907 | 0.270 |
Why?
| | Child, Preschool | 3 | 2025 | 4162 | 0.240 |
Why?
| | Rhabdomyosarcoma | 1 | 2025 | 13 | 0.240 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2025 | 62 | 0.230 |
Why?
| | Anthracyclines | 1 | 2025 | 35 | 0.230 |
Why?
| | Decision Support Techniques | 1 | 2025 | 73 | 0.230 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2025 | 83 | 0.220 |
Why?
| | Ifosfamide | 1 | 2024 | 9 | 0.220 |
Why?
| | Child | 4 | 2025 | 7379 | 0.210 |
Why?
| | Neoplasm Grading | 1 | 2024 | 128 | 0.210 |
Why?
| | Osteoblastoma | 1 | 2023 | 2 | 0.200 |
Why?
| | Osteoma, Osteoid | 1 | 2023 | 4 | 0.200 |
Why?
| | Neuroblastoma | 1 | 2023 | 55 | 0.200 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 233 | 0.200 |
Why?
| | Heart Diseases | 1 | 2025 | 221 | 0.190 |
Why?
| | Genes, APC | 1 | 2022 | 4 | 0.190 |
Why?
| | Doxorubicin | 1 | 2024 | 247 | 0.190 |
Why?
| | Combined Modality Therapy | 1 | 2024 | 640 | 0.180 |
Why?
| | Survival Rate | 1 | 2024 | 949 | 0.180 |
Why?
| | Humans | 10 | 2025 | 53230 | 0.180 |
Why?
| | Bone Neoplasms | 1 | 2023 | 188 | 0.170 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2020 | 9 | 0.160 |
Why?
| | RNA-Binding Protein EWS | 1 | 2020 | 14 | 0.160 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2020 | 30 | 0.160 |
Why?
| | Cyclin D1 | 1 | 2020 | 59 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 647 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 122 | 0.160 |
Why?
| | DNA Copy Number Variations | 1 | 2020 | 117 | 0.160 |
Why?
| | Female | 5 | 2025 | 28782 | 0.150 |
Why?
| | Carboxymethylcellulose Sodium | 1 | 2018 | 2 | 0.150 |
Why?
| | Infant | 2 | 2025 | 3805 | 0.150 |
Why?
| | Incidence | 1 | 2022 | 1085 | 0.150 |
Why?
| | Glycerol | 1 | 2018 | 19 | 0.150 |
Why?
| | Dry Eye Syndromes | 1 | 2018 | 11 | 0.150 |
Why?
| | Follow-Up Studies | 1 | 2024 | 2318 | 0.150 |
Why?
| | Gene Expression Profiling | 1 | 2023 | 1112 | 0.140 |
Why?
| | Prospective Studies | 1 | 2024 | 2411 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1043 | 0.140 |
Why?
| | Immunohistochemistry | 1 | 2020 | 975 | 0.130 |
Why?
| | Treatment Outcome | 3 | 2025 | 5595 | 0.120 |
Why?
| | Skin Neoplasms | 1 | 2020 | 500 | 0.110 |
Why?
| | Young Adult | 1 | 2024 | 4511 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 1583 | 0.100 |
Why?
| | Retrospective Studies | 1 | 2024 | 6819 | 0.090 |
Why?
| | Adult | 2 | 2024 | 14534 | 0.080 |
Why?
| | Male | 3 | 2025 | 27435 | 0.070 |
Why?
| | Troponin T | 1 | 2025 | 13 | 0.060 |
Why?
| | Receptors, CXCR4 | 1 | 2025 | 30 | 0.060 |
Why?
| | Cyclophosphamide | 1 | 2025 | 178 | 0.060 |
Why?
| | Cell Movement | 1 | 2025 | 279 | 0.050 |
Why?
| | Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2023 | 2 | 0.050 |
Why?
| | Fibroblasts | 1 | 2025 | 363 | 0.050 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 274 | 0.050 |
Why?
| | Polypyrimidine Tract-Binding Protein | 1 | 2023 | 11 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2023 | 60 | 0.050 |
Why?
| | Pilot Projects | 1 | 2025 | 726 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 350 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2025 | 934 | 0.050 |
Why?
| | Disease Progression | 1 | 2025 | 880 | 0.050 |
Why?
| | Age Factors | 1 | 2025 | 1136 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2025 | 1219 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2025 | 1031 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2025 | 1470 | 0.040 |
Why?
| | Risk Assessment | 1 | 2025 | 1368 | 0.040 |
Why?
| | Transcriptome | 1 | 2023 | 367 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2023 | 1038 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2025 | 645 | 0.040 |
Why?
| | Time Factors | 1 | 2025 | 2991 | 0.040 |
Why?
| | Viscosity | 1 | 2018 | 8 | 0.040 |
Why?
| | Administration, Ophthalmic | 1 | 2018 | 4 | 0.040 |
Why?
| | Tears | 1 | 2018 | 13 | 0.040 |
Why?
| | Ophthalmic Solutions | 1 | 2018 | 20 | 0.040 |
Why?
| | Drug Combinations | 1 | 2018 | 138 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2018 | 729 | 0.030 |
Why?
| | Risk Factors | 1 | 2025 | 4017 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2023 | 2913 | 0.030 |
Why?
| | Aged | 1 | 2018 | 10429 | 0.010 |
Why?
| | Middle Aged | 1 | 2018 | 13419 | 0.010 |
Why?
|
|
Douglass's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|